Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month
regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in
recurrent implantation failure (RIF) patients with latent genital tuberculosis (LGTB),
compared to no treatment and non-LGTB patients.